Fertility and Sterility
Volume 93, Issue 2 , Pages 586-591, 15 January 2010

A prospective, randomized, double-blinded study of assisted hatching in women younger than 38 years undergoing in vitro fertilization

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri

Received 26 October 2008; received in revised form 24 December 2008; accepted 19 January 2009. published online 06 March 2009.

Objective

To determine whether assisted hatching is beneficial to IVF patients younger than 38 years whose embryos have a thickened zona pellucida (ZP).

Design

Prospective, randomized, double-blinded, crossover study.

Setting

University-based infertility center.

Patient(s)

One hundred twenty-one women less than 38 years of age, undergoing IVF at Washington University between April 2004 and February 2007, with ZP thickness ≥13 μm for any embryos.

Intervention(s)

Measurement of ZP thickness in embryos undergoing IVF; randomization of women with embryos with ZP thickness ≥13 μm to no procedure or assisted hatching performed by acidic Tyrode's solution.

Main Outcome Measure(s)

Clinical intrauterine pregnancy rate, implantation rate, spontaneous pregnancy loss, and live birth rate.

Result(s)

Baseline characteristics and ZP thickness were not significantly different between the two study arms (hatched and unhatched). No significant differences were observed between hatched and unhatched patients in the rates of clinical pregnancy (47% vs. 50% respectively) or live birth (46% vs. 45% respectively). Further, no significant differences were noted between hatched and unhatched groups in rates of spontaneous abortions, monozygotic twinning, dizygotic twinning, chromosomal abnormalities, or ectopic gestations. In addition, mean ZP thickness did not have a significant effect on pregnancy.

Conclusion(s)

In patients younger than 38 years with embryos with ZP thickness of ≥13 μm, assisted hatching does not improve the rates of implantation, clinical pregnancy, or live birth, and thus does not appear to offer any benefit to patients in this age group undergoing IVF.

Key Words: In vitro fertilization, zona pellucida, pregnancy, clinical trial

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by Barnes-Jewish Hospital Foundation.

 A.R.H. has nothing to disclose. S.E.L. has nothing to disclose. E.S.J. has nothing to disclose. A.S.C. has nothing to disclose. V.S.R. has nothing to disclose. R.R.O. has nothing to disclose.

PII: S0015-0282(09)00237-4

doi:10.1016/j.fertnstert.2009.01.116

Fertility and Sterility
Volume 93, Issue 2 , Pages 586-591, 15 January 2010